Benefits of Cabazitaxel in Advanced Stages of Prostate Cancer

Benefits of Cabazitaxel in Advanced Stages of Prostate Cancer
shutterstock_171525971A recent study entitled “Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer” published in Clinical Cancer Research showed that cabazitaxel, a new member of the taxane family and FDA approved drug, may be more efficient for treating some prostate cancer patients, a hypothesis now being tested in clinical trials. In the United States, prostate cancer is the second most common type of cancer in men, with taxanes comprising the only class of chemotherapeutics available to treat this type of cancer. To improve the outcomes of patients with castration-resistant prostate cancer (CRPC) there is an urgent need for more effective therapies and approaches with specific treatments. For a long time, docetaxel has been the most effective chemotherapy for patients with prostate cancer that were non-responsive to hormone therapy. Cabazitaxel belongs to the second generation of drugs within the taxanes family and was only applied in patients that did not respond to hormone and docetaxel therapy. Study author Dr. Karen Knudsen explained in a 
Subscribe or to access all post and page content.